Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 3/20 | 0.47 |
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.40 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.40 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.40 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.40 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.40 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.40 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.40 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.39 |
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | TSHR | P16473 | 4/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.49 |
| ▸ | RECQL | P46063 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27946264 | 1.00 | ALDH1A1 (0.49) | ALDH1A1TSHRHSD17B10RECQLKDM4E | |
| SCHEMBL6696812 | 0.98 | KDM4E (0.48) | ALDH1A1TSHRHSD17B10RECQLKDM4E | |
| SCHEMBL1755233 | 0.77 | KEAP1 (0.46) | ALDH1A1TSHRHSD17B10RECQLKDM4E | |
| Hydrochloric Acid SCHEMBL28740125 | 0.76 | PABPC1 (0.55) | ALDH1A1TSHRHSD17B10RECQLKDM4E | |
| SCHEMBL4652710 | 0.76 | TSHR (0.48) | ALDH1A1TSHRHSD17B10RECQLKDM4E | |
| SCHEMBL20715566 | 0.76 | ALDH1A1 (0.44) | ALDH1A1TSHRHSD17B10RECQLKDM4E | |
| SCHEMBL3072881 | 0.75 | KDM4E (0.59) | ALDH1A1HSD17B10KDM4EGAACA12 | |
| SCHEMBL3070481 | 0.75 | ALDH1A1 (0.53) | ALDH1A1TSHRHSD17B10RECQLKDM4E | |
| SCHEMBL3072884 | 0.75 | KDM4E (0.59) | ALDH1A1HSD17B10KDM4EGAACA12 | |
| SCHEMBL3070479 | 0.75 | ALDH1A1 (0.53) | ALDH1A1TSHRHSD17B10RECQLKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102687860-A | Method for producing aqueous dispersion containing high concentration nano/submicron hydrophobic functional compound | FOOD INDUSTRY RES & DEV INST | 2012-09-26 | — | — | CN | disclosed |
| US-7740888-B2 | Extracts of passion fruit and uses thereof | INDUSTRIAL RESEARCH LIMITED (NZ) | 2010-06-22 | — | — | US | disclosed |
| US-7691423-B2 | Method of treating inflammation disorders using extracts of passion fruit | INDUSTRIAL RESEARCH LIMITED (NZ) | 2010-04-06 | — | — | US | disclosed |
| US-7687089-B2 | Extracts of passion fruit and uses thereof | INDUSTRIAL RESEARCH LIMITED (NZ) | 2010-03-30 | — | — | US | disclosed |
| EP-1854470-B1 | Method of treating inflammation disorders using extracts of passion fruit | IND RES LTD L L C (NZ) | 2010-03-03 | — | — | EP | disclosed |
| WO-2010011591-A1 | METHOD OF TREATING INFLAMMATION DISORDERS USING EXTRACTS OF PASSION FRUIT | KEMIN FOODS, L.C. (US) | 2010-01-28 | — | — | WO | disclosed |
| EP-1763360-A4 | EXTRACTS OF PASSION FRUIT AND USES THEREOF | IND RES LTD L L C (NZ) | 2009-08-19 | — | — | EP | disclosed |
| US-20090041878-A1 | EXTRACTS OF PASSION FRUIT AND USES THEROF | CALLAGHAN INNOVATION (NZ) | 2009-02-12 | — | — | US | disclosed |
| US-20090022832-A1 | METHOD OF TREATING INFLAMMATION DISORDERS USING EXTRACTS OF PASSION FRUIT | CALLAGHAN INNOVATION (NZ) | 2009-01-22 | — | — | US | disclosed |
| US-20080305194-A1 | EXTRACTS OF PASSION FRUIT AND USES THEREOF | CALLAGHAN INNOVATION (NZ) | 2008-12-11 | — | — | US | disclosed |
| US-7390517-B2 | Extracts of passion fruit and uses thereof | CALLAGHAN INNOVATION (NZ) | 2008-06-24 | — | — | US | disclosed |
| EP-1854470-A1 | Method of treating inflammation disorders using extracts of passion fruit | Industrial Research Limited, L.L.C. (NZ) | 2007-11-14 | — | — | EP | disclosed |
| EP-1763360-A2 | EXTRACTS OF PASSION FRUIT AND USES THEREOF | Industrial Research Limited, L.L.C. (NZ) | 2007-03-21 | — | — | EP | disclosed |
| US-20060280821-A1 | Method of treating inflammation disorders using extracts of passion fruit | SOUTHWEST SCIENTIFIC EDITING AND CONSULTING LLC | 2006-12-14 | — | — | US | disclosed |
| US-20060222725-A1 | Extracts of passion fruit and uses thereof | CALLAGHAN INNOVATION (NZ) | 2006-10-05 | — | — | US | disclosed |
| WO-2005097153-A2 | EXTRACTS OF PASSION FRUIT AND USES THEREOF | INDUSTRIAL RESEARCH LIMITED, L.L.C. (NZ) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305194-A1 | EXTRACTS OF PASSION FRUIT AND USES THEREOF | NOS2, NOS3, NOS1 | GAA 2769/4885GRIN2D 3808/4885GRIN3B 2853/4885 |
| US-20060280821-A1 | Method of treating inflammation disorders using extracts of passion fruit | IL5, IL6, TNF | GAA 2437/4885GRIN2D 4737/4885GRIN3B 4360/4885 |
| US-20090041878-A1 | EXTRACTS OF PASSION FRUIT AND USES THEROF | FABP1, TUFM, NOS3 | GAA 2773/4885GRIN2D 2963/4885GRIN3B 2329/4885 |
| US-20090022832-A1 | METHOD OF TREATING INFLAMMATION DISORDERS USING EXTRACTS OF PASSION FRUIT | IL5, IL6, TNF | GAA 2437/4885GRIN2D 4737/4885GRIN3B 4360/4885 |
| US-20060222725-A1 | Extracts of passion fruit and uses thereof | NOS2, NOS3, NOS1 | GAA 2769/4885GRIN2D 3808/4885GRIN3B 2853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.